Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Average Recommendation of “Buy” from Analysts

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) have been given a consensus recommendation of “Buy” by the nine research firms that are currently covering the company, MarketBeat Ratings reports. Eight investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $15.72.

VYGR has been the topic of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Voyager Therapeutics in a report on Monday, January 27th. Leerink Partners started coverage on shares of Voyager Therapeutics in a research note on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 price target on the stock. Canaccord Genuity Group reiterated a “buy” rating and set a $14.00 price objective on shares of Voyager Therapeutics in a research report on Thursday, November 14th. Citigroup assumed coverage on Voyager Therapeutics in a research report on Monday, December 2nd. They issued a “buy” rating and a $12.00 target price on the stock. Finally, StockNews.com downgraded Voyager Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, December 13th.

Insider Transactions at Voyager Therapeutics

In other news, COO Robin Swartz sold 6,500 shares of the firm’s stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $5.65, for a total transaction of $36,725.00. Following the completion of the transaction, the chief operating officer now owns 112,328 shares in the company, valued at approximately $634,653.20. This trade represents a 5.47 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In the last 90 days, insiders have sold 10,778 shares of company stock valued at $58,548. Corporate insiders own 4.53% of the company’s stock.

Institutional Trading of Voyager Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Hunter Perkins Capital Management LLC boosted its position in shares of Voyager Therapeutics by 3.3% in the 3rd quarter. Hunter Perkins Capital Management LLC now owns 64,040 shares of the company’s stock valued at $375,000 after purchasing an additional 2,025 shares during the period. Empowered Funds LLC lifted its stake in Voyager Therapeutics by 5.4% during the third quarter. Empowered Funds LLC now owns 44,809 shares of the company’s stock valued at $262,000 after buying an additional 2,278 shares in the last quarter. Rhumbline Advisers boosted its holdings in shares of Voyager Therapeutics by 3.4% in the fourth quarter. Rhumbline Advisers now owns 71,497 shares of the company’s stock worth $405,000 after buying an additional 2,354 shares during the period. Picton Mahoney Asset Management increased its position in shares of Voyager Therapeutics by 71.1% in the fourth quarter. Picton Mahoney Asset Management now owns 5,883 shares of the company’s stock worth $33,000 after acquiring an additional 2,444 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Voyager Therapeutics by 2.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 137,477 shares of the company’s stock valued at $804,000 after acquiring an additional 3,473 shares during the period. 48.03% of the stock is owned by institutional investors and hedge funds.

Voyager Therapeutics Stock Performance

Voyager Therapeutics stock opened at $4.20 on Wednesday. Voyager Therapeutics has a 1 year low of $4.13 and a 1 year high of $10.66. The firm’s 50-day moving average is $5.69 and its 200-day moving average is $6.33. The company has a market cap of $229.45 million, a P/E ratio of 5.92 and a beta of 0.91.

Voyager Therapeutics (NASDAQ:VYGR) last issued its earnings results on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.29. The company had revenue of $24.63 million during the quarter, compared to the consensus estimate of $12.63 million. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. During the same period in the previous year, the firm posted ($0.59) earnings per share. As a group, sell-side analysts predict that Voyager Therapeutics will post -0.91 earnings per share for the current year.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.